HOME >> BIOLOGY >> NEWS
Treatable psychiatric symptoms common with degenerative brain disease

Potentially treatable psychiatric problems are common in patients with degenerative brain diseases affecting movement and coordination, according to a study by Johns Hopkins scientists. Up to 80 per cent of those with either Huntington's disease or degenerative diseases affecting the cerebellum also suffer from depression, impaired thinking and changes in personality, the study found.

"Traditionally, there has been this distinction between neurological and psychiatric disorders, but it is an artificial distinction," said lead author Russell L. Margolis, M.D., associate professor of psychiatry at Hopkins and director of the Laboratory of Genetic Neurobiology.

"Indeed, the high rate of psychiatric disorders in these patients suggests that many, if not most, can benefit from treatment, even if the course of the brain disease itself cannot be reversed. Many symptoms can be eased, and the quality of life for these patients and their families can be greatly enhanced," says Margolis.

"Our findings of high rates of psychiatric disorders in Huntington's disease confirm the results of previous studies, and we believe we've found the first well-established link between serious psychiatric disorders and the cerebellum, a region at the back of the brain densely packed with nerve cells," notes Margolis.

In the study, Margolis and his colleagues conducted detailed interviews and analyzed brain images of three groups: 31 patients with degenerative cerebellar disease, 21 patients with Huntington's disease and 29 people who had no signs of brain disease. The results, reported in the August issue of the American Journal of Psychiatry, found that 77 per cent of patients with cerebellar disease had psychiatric disorders, and 81 per cent of Huntington's disease patients did so, rates nearly double those seen in healthy control subjects (41 per cent). Sixty-eight per cent of those with cerebellar disease suffered from mood disorders like depression, com
'"/>

Contact: Trent Stockton
tstockt1@jhmi.edu
410-955-8665
Johns Hopkins Medical Institutions
6-Aug-2002


Page: 1 2 3

Related biology news :

1. Brain serotonin enzyme finding might explain psychiatric disorders
2. Researchers caution against linking strep, neuropsychiatric disorders
3. New tool for studying animal models of neurological and psychiatric diseases
4. Environmental and genetic factors influence development of psychiatric disorder
5. Chronic respiratory symptoms prevalent among Alaska natives
6. Ritalin may improve Parkinsons symptoms, OHSU study says
7. UT Southwestern research halts narcolepsy symptoms
8. Dec. 17 JAMA study shows new biologic drug reduces psoriasis symptoms, improves quality of life
9. Imperial researchers show novel flu treatment eliminates symptoms in mice
10. Gene therapy delays death in mouse with symptoms of Lou Gehrigs disease
11. Spectrum of West Nile symptoms includes paralysis

Post Your Comments:
(Date:12/10/2014)... Dec. 9, 2014 CIE San Diego has ... provides the connective tissue that enhances care coordination among ... easily share client-level information; earned a second $1 million ... organizations serving seniors aging in community and; will be ... December 11 th 4-6p. CIE San ...
(Date:12/4/2014)... GARDENS, Fla. , Dec. 3, 2014 /PRNewswire/ ... solutions, today announced that its DigitalPersona ® ... fingerprint readers have been deployed throughout First Bank ... , South Carolina and ... in Southern Pines, North Carolina ...
(Date:11/21/2014)... Calif. , Nov. 20, 2014 Strict ... driver efficiency are piloting the North American and European ... of accidents growing, gesture recognition systems that are intuitive ... a mark in the industry. New ... Automotive Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 2Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 3Community Information Exchange San Diego Launches Pilot, Secures $1 Million Expansion Grant, and Becomes a "Live Well San Diego" Partner 4First Bank Partners with Crossmatch to Increase Log In Security 2First Bank Partners with Crossmatch to Increase Log In Security 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
(Date:12/17/2014)... (PRWEB) December 17, 2014 Gene ... that it has entered into a technology access ... (ADM) to apply DNA2.0’s proprietary protein engineering technology, ... process. , “We are extremely excited that the ... platform. This proprietary bioengineering technology has now ...
(Date:12/17/2014)... SOUTH SAN FRANCISCO, Calif. , Dec. 17, ... positive results of a Phase 2 study evaluating ... for the treatment of patients with severe, chronic ... the current standard of care, including topical steroids ... endpoint was percent change in Visual Analog Scale ...
(Date:12/15/2014)...  GlassesOff Inc. (OTCBB: GLSO) announced today the appointment ... director of the Company,s Board of Directors. ... its CEO until its acquisition by Stanley Black ... Recognized as the inventor of the first Wi-Fi-based Active ... -based RFID solutions focused on improving operational efficiency, safety ...
(Date:12/13/2014)... (PRWEB) December 12, 2014 Clarassance, a ... announced its new name: Therabron Therapeutics , Inc. ... and bronchioles (a type of structure in the lungs ... company’s mission to develop novel protein therapeutics for the ... directors decided to change the name to mark the ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 2Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 3Velocity Pharmaceutical Development, LLC and Tigercat Pharma, Inc. Announce Phase 2 Results for VPD-737 in Patients With Chronic Pruritus 4AeroScout Founder Joins GlassesOff's Board of Directors 2AeroScout Founder Joins GlassesOff's Board of Directors 3Maryland-based Biotech Company's Path Forward in Treating Respiratory Diseases Sparks Name Change 2
Cached News: